Abstract
Approximately 80% of patients who underwent attempted self-expanding transcatheter aortic valve replacement (TAVR) in the CoreValve US Trial Program (Pivotal and Continued Access Study [CAS]) had coronary artery disease. As the use of TAVR is being studied in lower-risk patients, the ability to
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
